Revised forecast
Fiscal year ending March 2027 · Full yearPrevious forecast published 13 May 2026The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Revenue and each profit measure are expected to fall below the previous forecast due to the postponement of the new brand launch and lower-than-expected sales of "Straine." The decline in gross profit and other factors was partly offset by curbing selling, general and administrative expenses such as advertising and promotion costs, while the adjusted net income forecast reflects a review of non-operating expenses and tax expense.
| Item | Details |
|---|---|
| Net Sales | 56,000～60,000 → ¥52,000 million（△13.3～△7.1） |
| Operating profit | 7,500～10,000 → ¥6,000 million（△40.0～△20.0） |
| Fiscal Period Covered | Fiscal year ending March 2027 |
| Period Covered | Full year |
| Publication date of previous forecast | 13 May 2026 |
| Previous-period results | Revenue ¥29,359 million, operating profit ¥3,802 million, adjusted EBITDA ¥3,850 million, adjusted net income ¥2,654 million (fiscal year ending March 2026, standalone) |
| Reason for the revision | Revenue and each profit measure are expected to fall below the previous forecast due to the postponement of the new brand launch and lower-than-expected sales of "Straine." The decline in gross profit and other factors was partly offset by curbing selling, general and administrative expenses such as advertising and promotion costs, while the adjusted net income forecast reflects a review of non-operating expenses and tax expense. |
| Dividend forecast revision | The year-end dividend forecast remains at no dividend, unchanged from the previous announcement. |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The main factors were the postponement of the new brand launch, the time required to establish repeat purchases of "Straine," and lower-than-expected sales due to a review of the initial product line's pricing and the coexistence of renewed products. While the decline in gross profit and other factors was partly offset by curbing selling, general and administrative expenses such as advertising and promotion costs, the adjusted net income forecast also reflects a review of non-operating expenses, including interest expense and financing fees, as well as tax expense.